ELF3 and type 2 diabetes mellitus: Based on in vitro studies, where the treatment of podocytes with AGEs induced the secretion of EVs enriched in an upstream target of TGF-β signaling pathway, the epithelium-specific transcription factor-3 (Elf3), the levels of Elf3+uEVs were evaluated as markers of podocyte injury in patients with T2DM and heavy proteinuria.